Improvement of glucose and lipid metabolism with pegylated interferon-α plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus
| Autor: | Yudong Wang, Guofeng Chen, Dong Ji, Bin-Fang Ling, Fan Li, Shao Qing, Xioaxia Niu, George Lau, Bing Li, Yu-Hua Meng |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Blood Glucose
Male Hepacivirus lcsh:Medicine medicine.disease_cause chemistry.chemical_compound Pegylated interferon biology virus diseases Alanine Transaminase Fasting General Medicine Hepatitis C Middle Aged Postprandial Period Cholesterol Liver Elasticity Imaging Techniques RNA Viral Drug Therapy Combination Female medicine.drug Adult China Genotype Hepatitis C virus Alpha interferon Antiviral Agents Ribavirin medicine Humans Triglycerides Glycated Hemoglobin business.industry lcsh:R Interferon-alpha Type 2 Diabetes Mellitus Lipid metabolism Hepatitis C Chronic Lipid Metabolism medicine.disease biology.organism_classification Virology digestive system diseases Diabetes Mellitus Type 2 chemistry Immunology business |
| Zdroj: | Annals of Saudi Medicine, Vol 35, Iss 4, Pp 293-297 (2015) |
| ISSN: | 0975-4466 0256-4947 |
| DOI: | 10.5144/0256-4947.2015.293 |
| Popis: | BACKGROUND: Many epidemiological studies have demonstrated a significant association between Type 2 diabetes mellitus and abnormal lipid profiles with chronic HCV genotype 1 (GT1) infection. We examined the impact on glucose and lipid profiles of treating Chinese patients using pegylated interferon (Peg-IFN)-α and ribavirin (RBV). METHODS: We conducted a hospital-based clinical study of Chinese patients chronically infected with GT1b HCV. All the patients were treated for 48 weeks (PR48) with Peg-IFN-α (180 μg once per week) or Peg-IFN-α (1.5 μg/kg once per week) plus RBV (15 mg/kg per day)). Fasting blood glucose (FBG), postprandial blood glucose (PBG-2h), glycosylated hemoglobin (HbA1c), total cholesterol (TC) and triglyceride (TG) levels, were measured at baseline, during therapy, at the end of therapy and at follow-up. In addition, liver stiffness (LS) by transient elastography, HCV RNA and ALT levels were also measured. RESULTS: We enrolled 116 patients. At the end of treatment (EOT) (week 48), HCV RNA was negative in all patients, 77.6% (90/116) of patients achieved sustained virologic response (SVR) 24 weeks after EOT, and 22.4% (26/116) did not achieve SVR. All parameters associated with liver inflammation, liver fibrosis, glucose and lipid metabolism had decreased significantly compared with baseline (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|